Comparative Analysis of Antithrombotic Therapy in In-Patients with Atrial Fibrillation
Abstract
Aim. To study the frequency of prescribing antithrombotic agents in patients with non-valvular atrial fibrillation (AF) who were hospitalized in the cardiology department of a multidisciplinary hospital.
Material and methods. A retrospective one-time study of medical records of 765 patients with non-valvular AF treated in the cardiology department of a multidisciplinary hospital in 2012 and 2016 was performed.
Results. All patients were stratified in three groups depending on the CHA2DS2-VASc score. The frequency of prescribing antithrombotic agents was evaluated in each group. A low risk of thromboembolic complications was found in 1% (n=3) of patients in 2012 and 0.6% (n=3) in 2016. All these patients received antithrombotic agents. CHA2DS2-VASc=1 was found in 6% (n=15) of patients with AF in 2012 and in 3.4% (n=17) in 2016. A significant number of patients in this group received anticoagulant therapy with vitamin K antagonists (warfarin) or with direct oral anticoagulants. A high risk of thromboembolic complications (CHA2DS2-VASc≥2) was found in 93% of patient (n=245) in 2012 and in 96% (n=482) in 2016. Anticoagulant therapy was prescribed in 70.2% (n=172) patients with high risk in 2012 and 80% (n=387) in 2016. However, some patients with high risk of thromboembolic complications did not have the necessary therapy.
Conclusion. Positive changes in the structure and frequency of prescribing anticoagulant drugs in patients with AF and a high risk of thromboembolic complications were found during the years studied.
About the Authors
V. I. Petrov
Volgograd State Medical University
Russian Federation
Russian Federation
MD, PhD, Professor, Academician of the Russian Academy of Science, Head of Chair of Clinical Pharmacology and Intensive Therapy with Clinical Pharmacology and Clinical Allergology, College of Advanced Medical Studies,
Pavshikh Bortsov pl. 1, Volgograd, 400131
O. V. Shatalova
Volgograd State Medical University
Russian Federation
Russian Federation
MD, PhD, Associate Professor, Chair of Clinical Pharmacology and Intensive Therapy with Clinical Pharmacology and Clinical Allergology, College of Advanced Medical Studies,
Pavshikh Bortsov pl. 1, Volgograd, 400131
A. S. Gerasimenko
Volgograd State Medical University
Russian Federation
Russian Federation
MD, Post-Graduate Student for PhD, Chair of Clinical Pharmacology and Intensive Therapy with Clinical Pharmacology and Clinical Allergology, College of Advanced Medical Studies,
Pavshikh Bortsov pl. 1, Volgograd, 400131
V. S. Gorbatenko
Volgograd State Medical University
Russian Federation
Russian Federation
MD, PhD, Assistant, Chair of Clinical Pharmacology and Intensive Therapy with Clinical Pharmacology and Clinical Allergology, College of Advanced Medical Studies,
Pavshikh Bortsov pl. 1, Volgograd, 400131
References
1. Bjorck S., Palaszewski B., Friberg L., Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44:3103-08. doi:10.1161/STROKEAHA. 113.002329.
2. Haim M., Hoshen M., Reges O. et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4:e001486. doi:10.1161/JAHA.114.001486.
3. Wolf P.A., Abbot R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Int Med. 1987;147:1561-4.
4. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962. doi:10.1093/eurheartj/ehw210.
5. Petrov V.I., Shatalova O.V., Maslakov A.S. Analysis of antithrombotic therapy in patients with permanent atrial fibrillation (pharmacoepidemiological study). Rational Pharmacotherapy in Cardiology. 2014;10(2):174-8 (In Russ.) doi:10.20996/1819-6446-2014-10-2-174-178.
6. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. RE-LY steering committee and investigators. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. doi:10.1056/NEJMoa0905561.
7. Patel M.R., Mahaffey K.W., Gard J. et al. Rivaroxaban vs warfarin in non-valvular atrial fibrillation. N Engl J Med. 2011;365:883-91. doi:10.1056/NEJMoa1009638. 8. Granger C.B., Alexander J.H., Mc Murray J.J. et al. ARISTOTLE committees and investigators. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. doi:10.1056/NEJMoa1107039.
8. Diagnosis and treatment of atrial fibrillation. Russian guidelines (2011). Rational Pharmacotherapy in Cardiology. 2011;7(4):5-80. (In Russ.). doi:10.20996/1819-6446-2011-7-4.
9. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi:10.1093/eurheartj/ehw210.
10. Loukyanov MM, Boytsov SA, Jakushin CC, et al. Diagnosis, treatment, concomitant cardiovascular disease and comorbidities in patients with a diagnosis of "atrial fibrillation" in a real outpatient practice (according to register REKVAZA cardiovascular diseases). Rational Pharmacotherapy in Cardiology. 2014;10(4):366-77 (In Russ.) doi: 10.20996/1819-6446- 2014-10-4-366-377.
11. Martsevich S.Y., Navasardyan A.R., Kutishenko N.P., et al. The experience of studying atrial fibrillation based on the PROFILE register. Cardiovascular Therapy and Prevention. 2014;13(2):35-9 (In Russ.) doi: 10.15829/1728-8800-2014-2-35-39.
12. Melekhov A.V., Gendlin G.Е., Dadashova E.F., et al. Dynamics of the use of antithrombotic drugs in patients with atrial fibrillation: own data and review of domestic registers. Russian Medical Journal. 2017;23(3):116-26 (In Russ.) doi: 10.18821/0869-2106-2017-23-3-116-126.
13. Gaisenok O.V., Leonov A.S. The use of oral anticoagulants in patients with atrial fibrillation: cohort study data. Rational Pharmacotherapy in Cardiology. 2016;12(4):376-79. (In Russ.) doi: 10.20996/1819-6446-2016-12-4-376-379.
14. O'Brien EC, Simon DN, Allen LA, et al. Reasons for Warfarin Discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014;68(4):487-94. doi: 10.1016/j.ahj.2014.07.002.
Review
For citations:
Petrov V.I., Shatalova O.V., Gerasimenko A.S., Gorbatenko V.S. Comparative Analysis of Antithrombotic Therapy in In-Patients with Atrial Fibrillation. Rational Pharmacotherapy in Cardiology. 2019;15(1):49-53. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-1-49-53
Views: 520
Email this article 